对格林巴利综合征治疗中常规方法与免疫球蛋白的使用效果进行对比探讨

Comparison of the Effects of Conventional Methods and Immunoglobulins in the Treatment of Guillain-Barre Syndrome

目的研究分析免疫球蛋白和常规方法治疗格林巴利综合征患者的临床效果。方法在该院2017年7月—2018年7月内接受的格林巴利综合征患者中随机选择62例为实验对象,62例患者按照入院顺序分为对照组(31例)和研究组(31例),31例对照组患者均实施医院常规的方法治疗,31例研究组患者实施常规治疗联合免疫球蛋白治疗,分别比较两组患者的治疗临床效果。结果研究组的有效率为93.5%,对照组的为74.1%,差异有统计学意义(χ~2=9.125,P<0.05),研究组患者的治疗总满意度为(96.7%),明显优于对照组患者的治疗总满意度(80.6%),差异有统计学意义(χ~2=5.846,P<0.05);研究组患者的治疗总有效率和治疗满意度明显高于对照组(P<0.05)。结论对格林巴利综合征患者应实施免疫球蛋白治疗,实验证明免疫球蛋白治疗的效果明显优于常规方法治疗,患者的活动能力、生活能力和治疗效果非常显著,因此,值得大力临床推广。

Objective To study the clinical effects of immunoglobulin and conventional methods in the treatment of patients with Guillain-Barre syndrome. Methods A total of 62 patients with Guillain-Barre syndrome who were admitted to our hospital from July 2017 to July 2018 were enrolled in the study. 62 patients were divided into control group(31 cases) and study group(31 cases) according to the order of admission, 31 patients in the control group were treated with conventional hospital treatment, and 31 patients in the study group were treated with conventional therapy combined with immunoglobulin therapy, and the clinical effects of the two groups were compared. Results The effective rate was 93.5% in the study group and 74.1% in the control group. The difference was statistically significant(χ^2=9.125, P<0.05). The total satisfaction rate of the study group was(96.7%), which was significantly better. The total satisfaction rate of treatment in the control group(80.6%) was statistically significant(χ^2=5.846, P<0.05). The total effective rate and treatment satisfaction of the study group were significantly higher than those of the control group(P<0.05). Conclusion Immunoglobulin therapy should be performed in patients with Guillain-Barre syndrome. The results show that the effect of immunoglobulin therapy is significantly better than that of conventional methods. The activity, life ability and therapeutic effect of patients are very significant. Therefore,it is worthy of clinical promotion.